Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124


Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer's Abeta Peptide.

Paris D, Patel N, Ganey NJ, Laporte V, Quadros A, Mullan MJ.

Int J Pept Res Ther. 2010;16(1):23-30.


HSPG-binding peptide corresponding to the exon 6a-encoded domain of VEGF inhibits tumor growth by blocking angiogenesis in murine model.

Lee TY, Folkman J, Javaherian K.

PLoS One. 2010 Apr 1;5(4):e9945. doi: 10.1371/journal.pone.0009945.


Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.

Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET, Hussain M.

Invest New Drugs. 2011 Dec;29(6):1432-40. doi: 10.1007/s10637-010-9420-8. Epub 2010 Mar 25. Erratum in: Invest New Drugs. 2011 Dec;29(6);1517-8. Cooney, Kathleen A [added]; Mathew, Paul [added]; Pienta, Kenneth J [added]; Escara-Wilke, June [added]; Doyle, Gerald [added]; Al-Hawary, Mahmoud [added]; Keller, Evan T [added].


Protein C inhibitor regulates both cathepsin L activity and cell-mediated tumor cell migration.

Fortenberry YM, Brandal S, Bialas RC, Church FC.

Biochim Biophys Acta. 2010 Jun;1800(6):580-90. doi: 10.1016/j.bbagen.2010.03.003. Epub 2010 Mar 15.


Expression and purification of functional epitope of pigment epithelium-derived factor in E. coli with inhibiting effect on endothelial cells.

Gong Q, Yang X, Cai W, Gao G, Yang Z.

Protein J. 2010 Apr;29(3):167-73. doi: 10.1007/s10930-010-9236-6.


The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo.

Vandercappellen J, Liekens S, Bronckaers A, Noppen S, Ronsse I, Dillen C, Belleri M, Mitola S, Proost P, Presta M, Struyf S, Van Damme J.

Mol Cancer Res. 2010 Mar;8(3):322-34. doi: 10.1158/1541-7786.MCR-09-0176. Epub 2010 Mar 9.


A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.

Nabors LB, Fiveash JB, Markert JM, Kekan MS, Gillespie GY, Huang Z, Johnson MJ, Meleth S, Kuo H, Gladson CL, Fathallah-Shaykh HM.

Arch Neurol. 2010 Mar;67(3):313-9. doi: 10.1001/archneurol.2010.16.


From combinatorial peptide selection to drug prototype (I): targeting the vascular endothelial growth factor receptor pathway.

Giordano RJ, Cardó-Vila M, Salameh A, Anobom CD, Zeitlin BD, Hawke DH, Valente AP, Almeida FC, Nör JE, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5112-7. doi: 10.1073/pnas.0915141107. Epub 2010 Feb 26.


Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.

Alessi P, Leali D, Camozzi M, Cantelmo A, Albini A, Presta M.

Eur Cytokine Netw. 2009 Dec;20(4):225-34. doi: 10.1684/ecn.2009.0175. Review.


Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model.

Koskimaki JE, Karagiannis ED, Tang BC, Hammers H, Watkins DN, Pili R, Popel AS.

BMC Cancer. 2010 Feb 1;10:29. doi: 10.1186/1471-2407-10-29.


A novel fragment derived from the beta chain of human fibrinogen, beta43-63, is a potent inhibitor of activated endothelial cells in vitro and in vivo.

Krajewska E, Lewis CE, Chen YY, Welford A, Tazzyman S, Staton CA.

Br J Cancer. 2010 Feb 2;102(3):594-601. doi: 10.1038/sj.bjc.6605495. Epub 2010 Jan 12.


Regulation of tumor angiogenesis by the local environment.

Hall K, Ran S.

Front Biosci (Landmark Ed). 2010 Jan 1;15:195-212. Review.


Current trends in the clinical development of peptide therapeutics.

Saladin PM, Zhang BD, Reichert JM.

IDrugs. 2009 Dec;12(12):779-84. Review.


Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone.

Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM.

Clin Cancer Res. 2009 Dec 1;15(23):7398-404. doi: 10.1158/1078-0432.CCR-09-1957. Epub 2009 Nov 17.


Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.

Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM, Lassman AB.

Neurology. 2009 Oct 13;73(15):1200-6. doi: 10.1212/WNL.0b013e3181bc0184.


Endostatin derivative angiogenesis inhibitors.

Zheng MJ.

Chin Med J (Engl). 2009 Aug 20;122(16):1947-51. Review.


The anti-tumor properties of two tumstatin peptide fragments in human gastric carcinoma.

Li YJ, Sun LC, He Y, Liu XH, Liu M, Wang QM, Jin XM.

Acta Pharmacol Sin. 2009 Sep;30(9):1307-15. doi: 10.1038/aps.2009.111. Epub 2009 Aug 24.


Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide.

Leali D, Bianchi R, Bugatti A, Nicoli S, Mitola S, Ragona L, Tomaselli S, Gallo G, Catello S, Rivieccio V, Zetta L, Presta M.

J Cell Mol Med. 2010 Aug;14(8):2109-21. doi: 10.1111/j.1582-4934.2009.00855.x. Epub 2010 Jul 20.


The YSNSG cyclopeptide derived from tumstatin inhibits tumor angiogenesis by down-regulating endothelial cell migration.

Thevenard J, Ramont L, Devy J, Brassart B, Dupont-Deshorgue A, Floquet N, Schneider L, Ouchani F, Terryn C, Maquart FX, Monboisse JC, Brassart-Pasco S.

Int J Cancer. 2010 Mar 1;126(5):1055-66. doi: 10.1002/ijc.24688.

Supplemental Content

Support Center